Allergy Research Group, Inc. Reports Increased Earnings Before Tax for Third Quarter

HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 15, 2004--Allergy Research Group, Inc. (OTCBB:ALRG - News) announced financial results for the third quarter ending September 30, 2004.

ALRG recorded total revenue of $3,723,401 for the quarter, up 12% from 2003. The increase of $396,444 is primarily due to increased sales to distributors and increased demand at retail and wholesale for current and new products.

Cost of sales increased $177,930 to $2,076,622 for the quarter ended September 30, 2004, compared to $1,898,692 for the quarter ended September 30, 2003. The increase in cost of sales corresponds with the increase in sales. Gross profit margins increased approximately 1% as a result of higher profit margins associated with retail sales. Gross profit margins were approximately 44% at September 30, 2004.

During the quarter ended September 30, 2004, the Company recorded net earnings before tax of $618,221 as compared to net earnings before tax of $436,065 for the same period in 2003. The increase is a result of increased sales partially offset by a small increase in operating expenses (approximately $40,000). Due to an increase in the provision for income tax and change in deferred taxes, net income for the third quarter 2004 is $354,336 compared to $397,517 for the same period last year.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Increased Earnings Before Tax for Second Quarter

HAYWARD, Calif., Aug 12, 2004 (BUSINESS WIRE) -- Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the second quarter ending June 30, 2004.

ALRG recorded total revenue of $3,832,360 for the quarter, up 11% from 2003. The increase of $385,230 is primarily due to increased sales to distributors and increased demand at retail for current and new products.

Cost of sales increased $177,365 to $2,167,845 for the quarter ended June 30, 2004, compared to $1,990,480 for the quarter ended June 30, 2003. The increase in cost of sales corresponds with the increase in sales. Gross profit margins increased approximately 1% as a result of higher profit margins associated with retail sales. Gross profit margins were approximately 43% at June 30, 2004.

During the quarter ended June 30, 2004, the Company recorded net earnings before tax of $633,646 as compared to net earnings before tax of $468,899 for the same period in 2003. The increase is a result of increased sales partially offset by increased operating expenses. Due to an increase in the provision for income tax and change in deferred taxes, net income for the second quarter 2004 is $344,962 compared to $427,448 for the same period last year.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Increased Sales for First Quarter

HAYWARD---------May 13, 2004--------Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the first quarter ending March 31, 2004.

ALRG recorded total revenue of $3,724,899 for the quarter, up 8% from 2003. The increase of $276,137 is primarily due to increased sales to distributors and increased demand at retail for current and new products.

Cost of sales increased $179,779 to $2,134,619 for the quarter ended March 31, 2004, compared to $1,954,840 for the quarter ended March 31, 2003. The increase in cost of sales corresponds with the increase in sales. Gross profit margins decreased approximately .6%, approximating 42.7% for 2004 as a result of a slight increase in discounts allowed and cost of material.

During the quarter ended March 31, 2004, the Company recorded income before tax of $599,708 as compared to income before tax of $550,972 for the same period in 2003. The increase is a reflection of the increase in sales offset by increased operating expenses. Due to the difference in timing between the two years of the utilization of net operating loss carryforwards net income for the first quarter 2004 is $384,063 compared to $502,266 for the same period last year.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Record Profits For 2003

HAYWARD---------March 30, 2004--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2003.

ALRG announces record earnings of $1,643,770 for the year ended December 31, 2003, an increase of 64.73% compared to $997,862 for the same period ending December 31, 2002. Revenues reached $13,652,856 for the year, up 8% from 2002. The increase of $968,443 is primarily due to effective marketing efforts, the introduction of new products and the continued growth in sales of existing products.

“The quality of our hypoallergenic nutritional supplements and the successful launch of new products provides the impetus to maintain our current level of growth,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D., who has implemented a strategy that includes a new and comprehensive management team, tighter cost controls, and the further development of the sales and marketing approach.

Cost of sales increased $236,163 to $7,823,958 for the year ended December 31, 2003, compared to $7,587,795 for the year ended December 31, 2002, a corresponding increase resulting from the increase in sales. Gross profit margins increased approximately 2.5%, to 42.7% for the year 2003.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)